GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (NAS:BIIB) » Definitions » Long-Term Debt

BIIB (Biogen) Long-Term Debt : $4,547 Mil (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Biogen Long-Term Debt?

Biogen's Long-Term Debt for the quarter that ended in Dec. 2024 was $4,547 Mil.

Biogen's quarterly Long-Term Debt declined from Jun. 2024 ($6,292 Mil) to Sep. 2024 ($4,546 Mil) but then increased from Sep. 2024 ($4,546 Mil) to Dec. 2024 ($4,547 Mil).

Biogen's annual Long-Term Debt increased from Dec. 2022 ($6,281 Mil) to Dec. 2023 ($6,788 Mil) but then declined from Dec. 2023 ($6,788 Mil) to Dec. 2024 ($4,547 Mil).

Biogen Long-Term Debt Historical Data

The historical data trend for Biogen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Long-Term Debt Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,426.20 6,274.00 6,281.00 6,788.20 4,547.20

Biogen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,788.20 6,290.10 6,292.00 4,545.80 4,547.20

Biogen  (NAS:BIIB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biogen Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (NAS:BIIB) » Definitions » Long-Term Debt
Comparable Companies
OGN AMRN SCLX MDCX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY LSE:GSK TSE:4519
Traded in Other Exchanges
BIIB:Mexico BIIB_KZ:Kazakhstan 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Executives
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Priya Singhal officer: Head of Development C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Jane Grogan officer: Head of Research BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Susan Langer director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Ginger Gregory officer: EVP, Human Resources C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Adam Keeney officer: Head of Corporate Development BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Christopher Viehbacher director, officer: President and CEO C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Susan H Alexander officer: EVP, General Counsel C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Nicole Murphy officer: Head of Pharm Ops and Tech BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Rachid Izzar officer: Head of Alzheimer's Disease BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Alfred Sandrock officer: Grp SVP, Chief Medical Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Chirfi Guindo officer: EVP Glob. Mkt Acc & Cust Innov C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Jones William D /ca/ director